7 results about "Cns disease" patented technology

This article describes amide prodrugs, methods for preparing such compounds, pharmaceutical compositions and medicines comprising such compounds, and methods for using such compounds in the treatment of CNS diseases or conditions.

This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.

There is disclosed a compound of Formula (I):and any pharmaceutically acceptable salt or zwitterion thereof; wherein: R is hydrogen, methyl or ethyl; R1 is hydrogen or C1-C2 alkoxy; R2 is methyl or a C2-C4 group which may be saturated or unsaturated, branched or linear; and R3, R4, R5 and R6 each are independently selected from hydrogen, hydroxyl, halogen, methyl optionally substituted with hydroxy, methoxy, ethoxy, and a saturated or unsaturated C2-C3 that may be optionally substituted with hydroxyl, with the provisos that: (i) at least two of R4, R5, R6 and R7 must be hydrogen, and (ii) R3, R4, R5 and R6 may be selected such that an adjacent pair thereof join to form a ring having at least 5 members. The compound of Formula (I) is believed useful in treating a disease or disorder in a subject which may be alleviated by a 5HT2A agonist (e.g., CNS disorders and one or more symptoms of any one of depression, alcoholism, tobacco addiction, cocaine addiction, inflammation, cluster headache and PTSD in a subject).

Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.

The present invention provides a binding molecule which is capable of funding to the human NogoApolypeptide or human NiG with a dissociation constant < 1000nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule, an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and / or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the pefipheral (PNS) and / or centraI (CNS) nervous system.